$0.49
-0.02 (-3.02%)
Open$0.52
Previous Close$0.50
Day High$0.52
Day Low$0.48
52W High$1.45
52W Low$0.48
Volume—
Avg Volume38.6K
Market Cap2.27M
P/E Ratio—
EPS$-5.61
SectorBiotechnology
Analyst Ratings
Strong Buy
7 analysts
Price Target
+953.7% upside
Current
$0.49
$0.49
Target
$5.14
$5.14
$3.59
$5.14 avg
$6.80
Key Financials
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 484.7K | 468.9K | 455.7K |
| Net Income | -93,000 | -114,838 | -98,507 |
| Profit Margin | -19.2% | -24.5% | -21.6% |
| EBITDA | -101,936 | -104,145 | -94,610 |
| Free Cash Flow | -84,967 | -104,034 | -103,597 |
| Rev Growth | +6.2% | -0.5% | +16.3% |
| Debt/Equity | 0.77 | 0.85 | 0.69 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $264.34 | -0.29% | 74.3 | 468.50B |
| AMGN | Amgen Inc | $414.61 | +2.11% | 25.1 | 219.78B |
| GILD | Gilead Sciences Inc | $150.93 | +0.83% | — | 185.02B |
| VRTX | Vertex Pharmaceuticals Inc | $526.19 | +0.73% | 30.5 | 134.17B |
| REGN | Regeneron Pharmaceuticals | $788.04 | -1.00% | 18.8 | 81.31B |
| ALNY | Alnylam Pharmaceuticals Inc | $255.96 | +2.55% | 41.4 | 33.44B |